STOCK TITAN
  1. Home
  2. News
  3. NAOV

NanoVibronix Inc - NAOV STOCK NEWS

Welcome to our dedicated news page for NanoVibronix (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on NanoVibronix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NanoVibronix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NanoVibronix's position in the market.

News
NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024
Rhea-AI Summary
NanoVibronix, Inc. (Nasdaq: NAOV) will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024. The CEO, Brian Murphy, will host the presentation. Investors can access the live webcast and book 1x1 meetings at the conference venue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
NanoVibronix Issues Letter to Stockholders
Rhea-AI Summary
NanoVibronix, Inc. (NAOV) reported record revenues of $1.2 million in Q4 2023, alongside a loss of $702,000. The company focuses on developing and commercializing therapeutic devices like UroShield, PainShield, and WoundShield. Despite challenges in obtaining full approval for PainShield from CMS, NanoVibronix is seeing growth in domestic and international markets. The company is also conducting a RCT study with the University of Michigan to evaluate the efficacy of UroShield.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
none
-
News
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
Rhea-AI Summary
NanoVibronix, Inc. (NAOV) partners with Veranex, Inc. to enhance UroShield and PainShield products, aiming to add therapeutic functionality and cut costs. The collaboration focuses on research and development services to innovate the next generation of devices, ensuring improved quality and reduced expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
none
News
NanoVibronix Featured in Your Bladder Health Magazine
Rhea-AI Summary
NanoVibronix, Inc. (NASDAQ: NAOV) announced that its UroShield device is featured in Your Bladder Health Magazine for its effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and blockages. The article includes patient testimonials highlighting the positive impact on quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
none
-
News
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity
Rhea-AI Summary
NanoVibronix, Inc. (NASDAQ: NAOV) has entered into a non-binding letter of intent with APOGEPHA Arzneimittel GmbH to study the potential for APOGEPHA to distribute NanoVibronix’s UroShield product in Germany and other European markets. APOGEPHA, with a history of over 100 years, is a dedicated specialist in the field of urology. The goal is to better understand the feasibility of a distribution deal between both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
News
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
Rhea-AI Summary
NanoVibronix, a medical device company listed on Nasdaq as NAOV, has signed a Research Agreement with the University of Michigan for a Randomized Control Trial study of UroShield. The company aims to gather additional clinical evidence to support an application to the FDA for permanent clearance of UroShield, a Portable Ultrasonic Therapeutic Device. The study will focus on the impact of UroShield on reducing urinary tract infections, catheter blockages, and pain, and improving the quality of life for nursing home residents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.87%
Tags
clinical trial
News
NanoVibronix Regains Nasdaq Compliance
Rhea-AI Summary
NanoVibronix, Inc. (NAOV) received official notice of compliance from The Nasdaq Stock Market LLC, meeting all criteria for continued listing, including the minimum stockholders' equity requirement of $2.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.16%
Tags
none
-
News
NanoVibronix Issues Letter to Shareholders
Rhea-AI Summary
NanoVibronix, Inc. (NASDAQ: NAOV) provided a review of Q3 2023 and recent business developments in a letter to shareholders from CEO Brian Murphy. The company recorded Q3 revenues of $458,000, with a loss from operations of $670,000. International progress in the UK and Australia/New Zealand, domestic sales expansion, product development, reimbursement efforts, and research updates were highlighted. The company aims to drive profitable growth by expanding distribution, licensing channels, and engaging consumers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
-
News
NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1
Rhea-AI Summary
NanoVibronix, Inc. (Nasdaq: NAOV) has received a stocking order from its U.K. distribution partner, Peak Medical Limited, in anticipation of increased demand for its UroShield actuators, which are now eligible for reimbursement on NHS Prescription Services’ Drug Tariff effective November 1. The company is ramping up production to meet the expected surge in demand, and the U.K. distribution partner is working to educate healthcare providers on the product's benefits and accept orders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
none
News
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
Rhea-AI Summary
NanoVibronix receives reimbursement approval for UroShield actuators from NHS, allowing increased distribution to NHS patients. Contract with NHS Supply Chain extended for up to four years. Clinicians can prescribe UroShield beginning Nov 1, 2023. NHS will cover the cost. Positive impact on patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock NAOV logo
NanoVibronix Inc

Nasdaq:NAOV

NAOV Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NAOV Stock Data

2.12M
2.54M
0.42%
12.01%
0.13%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Elmsford

About NAOV

nanovibronix inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology. the company's patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. this unique development may be utilized for a variety of medical requiring low cost therapeutic ultrasound applications. the company's patch based product diagnosis, painshield®, carries an fda clearance. nanovibronix catheter based products include the cathbottm . nanovibronix inc. is located in elmsford, ny. its subsidiary, nanovibronix ltd. is located in nesher, israel.